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The ethics committee of Jagiellonian University 
in Kraków approved the study and patients signed 
a written informed consent form. The study was 
carried out in accordance with the Declaration of 
Helsinki and its amendments.
Laboratory investigations Blood samples (vol/vol, 
9:1 of 3.2% trisodium citrate) were spun at 2000 g 
for 10 minutes, and the supernatants were al‑
iquoted and stored at a temperature of –80ºC. 
Plasma levels of the C1INH antigen (aC1INH) 
were measured using nephelometry (Siemens 
Healthcare Diagnostics GmbH, Marburg, Ger‑
many). The functional activity of C1INH was de‑
termined using the functional chromogenic assay 
Berichrom C1INH (Siemens Healthcare Diagnos‑
tics). All patients had reduced serum C1INH levels 
(mean, 0.07 g/l; reference range, 0.21–0.39 g/l) 
and functional activity of C1INH (mean func‑
tional activity of C1INH, 26.0%; reference range, 
70%–130%). Plasma levels of factor VIII (FVIII; 
based on activated partial thromboplastin time) 
were evaluated using the Behring Coagulation 
System (Siemens Healthcare Diagnostics). ELI‑
SA test kits were used to measure thrombin–an‑
tithrombin complexes (TAT; Enzygnost TAT mi‑
cro, Siemens Healthcare Diagnostics).
Fibrin clot analysis Plasma fibrin clot permea‑
bility was determined as described previously.7 
The permeation coefficient (Ks), which indicates 
the average size of pores formed in the fibrin net‑
work (with low values indicating a tightly packed 
fibrin structure), was calculated from the equa‑
tion: Ks = Q × L × η/t × A × Δp, where Q is the flow 
rate in time, L is the length of a fibrin gel, η is 
the viscosity of liquid (in poise), t is percolating 
time, A is the cross ‑sectional area (in cm2), and 
Δp is a differential pressure (in dyne/cm2).
Introduction Hereditary angioedema (HAE) is 
a rare autosomal dominant disease caused by 
the deficiency of C1 inhibitor (C1INH). This HAE 
due to C1 inhibitor deficiency (C1INH ‑HAE) man‑
ifests as subcutaneous and submucosal angioede‑
ma, which can affect any part of the body.1
The deficiency of C1INH1,2 disturbs the comple‑
ment cascade, coagulation, kinins, and fibrinolysis 
and results in an uncontrolled release of bradyki‑
nin, the main mediator in C1INH ‑HAE.3 Previous 
studies supported the involvement of blood co‑
agulation and fibrinolysis in the pathophysiology 
of C1INH ‑HAE despite the absence of clinically 
relevant thrombosis and hemostatic disorders.4,5 
To our knowledge, there have been no reports on 
the properties of plasma fibrin clot in relation to 
thrombin formation in this disease despite evi‑
dence on their role in several pathologies.6
We sought to evaluate thrombin generation 
and fibrinolytic potential along with factor VIII 
and fibrin clot density in patients with C1INH‑
‑HAE during remission and acute angioedema 
attack.
Patients and methods Patients The study includ‑
ed 15 adult patients with C1INH ‑HAE in remis‑
sion and during angioedema attacks. The control 
group included 15 healthy individuals matched 
for age, sex, and body mass index. The diagnosis 
of C1INH ‑HAE was established on the basis of 
the patient and family history, on the examina‑
tion during attacks of angioedema, and reduced 
C1INH antigen as well as C1INH activity below 
50% of the reference values.1 The study was per‑
formed during remission (no attacks for at least 
2 weeks) and in the first 3 to 5 hours of acute an‑
gioedema attack. Patients with comorbidities and 
those receiving any long ‑term medication (includ‑
ing tranexamic acid or danazol) were ineligible.
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In remission, patients with C1INH ‑HAE 
had similar fibrinogen and TAT levels as con‑
trols (median [interquartile range (IQR)], 240 
[223–296] mg/dl vs 235 [215–287] mg/dl and 
3.68 [2.61–8.71] µg/l vs 3.03 [2.39–4.09] µg/l, 
respectively). Patients with C1INH ‑HAE were 
characterized by 35% higher FVIII levels (median 
[IQR], 139% [129%–149%] vs 103% [92%–107%]; 
P <0.05), 66.4% higher endogenous thrombin 
potential (median [IQR], 1994 [1719–2203] 
nM×min vs 1198 [989–1298] nM×min; P <0.05), 
and 106% higher peak thrombin compared with 
controls (median [IQR], 305 [280–341] nM vs 148 
[117–182] nM; P <0.05). In remission, Ks was lower 
by 19% (median [IQR], 6.05 [4.81–7.92] × 10–9 cm2 
vs 7.47 [6.62–9.01] × 10–9 cm2; P <0.05), while clot 
lysis time did not differ from the controls (medi‑
an [IQR], 95 [90–112] min vs 95 [85–105] min; 
P >0.05). There were no associations of throm‑
bin generation or fibrin clot properties with age, 
body mass index, or C1INH levels and activity in 
C1INH ‑HAE patients during remission.
Patients with C1INH ‑HAE during the attack 
compared with remission had 91.7% higher fi‑
brinogen levels, 325.8% higher TAT levels, and 
11.5% increased FVIII activity (TABLE 1). During 
the attack, FVIII levels were associated with peak 
thrombin (r = 0.55, P = 0.04), while a similar as‑
sociation in remission tended to be significant in 
remission (r = 0.5, P = 0.069). No other associa‑
tions were observed for FVIII activity and fibrin 
clot properties.
Of note, we have not found differences in TAT 
levels between patients with C1INH ‑HAE and 
with erythema marginatum (n [%], 8 [53.3]) 
and those without erythema (n [%], 7 [46.7]) 
regardless of whether the patients were in re‑
mission (median [IQR], 6.00 [2.91–11.52] vs 
3.68 [2.46–7.27] µg/l; P = 0.39) or during the at‑
tack (median [IQR], 39.74 [15.24–90.09] vs 7.82 
[4.14–47.33] µg/l; P = 0.12).
Discussion Our study is the first to show elevated 
FVIII activity and increased thrombin generation 
reflected by TAT and in vitro thrombin generation 
potential in patients with C1INH‑HAE. Howev‑
er, our results are based on a small group of pa‑
tients and should be confirmed in a larger study 
that would also assess coagulation factors (espe‑
cially von Willebrand factor) and their relation‑
ship with the duration and severity of an edema 
attack. Recently, increased thrombin generation 
assessed by CAT has been shown in patients with 
a chronic urticaria and a history of angioedema 
compared with patients with urticaria alone.10
An association between increased thrombin 
peak, elevated TAT, and FVIII levels may explain 
high D ‑dimer levels in patients with edema at‑
tacks, which are considered a biomarker of blood 
coagulation activation and fibrinolysis.5 Interest‑
ingly, increased FVIII activity in patients with 
C1INH ‑HAE during an angioedema attack and in 
remission is a novel observation. Recent studies 
have suggested the possible active involvement of 
Clot lysis time was measured using the as‑
say by Pieters et al.8 It was defined as the time 
from the midpoint of the clear ‑to ‑maximum‑
‑turbid transition, which represents clot forma‑
tion, to the midpoint of the maximum ‑turbid ‑to‑
‑clear transition.
Calibrated automated thrombogram Thrombin gen‑
eration kinetics were measured with a calibrated 
automated thrombogram (CAT; Thrombinoscope 
BV, Maastricht, the Netherlands) according to 
the manufacturer’s instructions.9 Each plasma 
sample was analyzed in duplicate. The maximum 
concentration of thrombin formed during the re‑
cording time was described as the thrombin peak 
and the area under the curve represented endog‑
enous thrombin potential.
Statistical analysis Categorical variables were 
analyzed by the Pearson χ2 test. Continuous vari‑
ables were expressed as median and interquartile 
range. Normality of the data was assessed using 
the Shapiro–Wilk test. The groups were compared 
using the t test for normally distributed continu‑
ous variables. For nonnormally distributed con‑
tinuous variables, the Mann–Whitney test and 
the Wilcoxon rank test were used. Associations 
between variables were assessed by the Spear‑
man rank correlation analysis. P values of less 
than 0.05 were considered significant.
Results Patients with C1INH ‑HAE did not dif‑
fer from age‑, sex‑, and body mass index–matched 
controls (all P >0.05). Eight patients (53.3%) had 
a positive family history of C1INH ‑HAE. The mean 
age of HAE onset was 9.9 years (range, 3–22 
years). In 8 patients, angioedema attacks were 
preceded by erythema marginatum.
TABLE 1 Characteristics of patients with hereditary angioedema due to C1 inhibitor 
deficiency during remission and attack
Variable Patients (n = 15)
In remission During attack
Age, y 36 (29.5–56.5)
Female sex, n (%) 11 (73.3)
Body mass index, kg/m2 24.6 (20.3–28.6)
Fibrinogen, mg/dl 240 (223–296) 460 (380–570)a
Factor VIII, % 139 (129–149) 155 (145–173)a
Fibrin clot permeability 
(Ks), ×10–9 cm2
6.05 (4.81–7.92) 5.94 (4.79–7.15)
Clot lysis time, min 95.0 (89.5–111.7) 91.4 (83.0–110.2)
Lag time, min 2.94 (2.78–3.61) 2.94 (2.47–3.43)
Endogenous thrombin potential, 
nM×min
1994 (1719–2203) 1940 (1624–2444)
Peak thrombin, nM 305 (280–341) 312 (271–394)
Time to peak thrombin, min 6.95 (6.29–7.5) 5.94 (5.33–6.62)
Thrombin–antithrombin complex, μg/l 3.68 (2.61–8.71) 5.67 (8.35–87.35)a
Data are presented as median (interquartile range) unless otherwise indicated.
a P <0.05 compared with patients in remission
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some blood clotting factors such as FXII and tis‑
sue factor–FVIIa complex2,11 in the pathomech‑
anism of C1INH ‑HAE.
We observed no difference in plasma fibrino‑
lytic potential and fibrin clot density between pa‑
tients with C1INH ‑HAE (regardless of remission 
or attack) and controls, despite elevated thrombin 
formation markers in the former group. This could 
explain, at least in part, the absence of thrombot‑
ic manifestations despite very high D ‑dimer lev‑
els found in patients with severe HAE attacks.5 
In most cases, efficient fibrinolysis seems to pro‑
tect against thrombosis. However, high thrombin 
formation might suggest clinical benefits from 
thromboprophylaxis in some patients with high 
D ‑dimer levels during a severe attack.
During attack, contact system activation re‑
sults in increased F1+F2 prothrombin fragment 
levels and shortening of activated partial throm‑
boplastin time,2 which indicates enhanced throm‑
bin generation due to FXII activation. Some au‑
thors2,11 reported that during attack, FVIIa lev‑
els are increased, suggesting that self ‑limiting 
thrombin generation may be due to the activa‑
tion of the tissue factor pathway. This phenom‑
enon under bradykinin control as suggested by 
Dong et al11 deserves further research. Throm‑
bin generation during attack activates thrombin 
activatable fibrinolysis inhibitor, which may in‑
dicate its effect on the regulation of fibrinolysis 
in this clinical setting. The involvement of endo‑
thelial activation in the pathogenesis of C1INH‑
‑HAE is in line with the study by Kajdácsi et al,12 
who showed a significantly increased activity of 
von Willebrand factor.
Our study shows that thrombin generation re‑
lated with increased FVIII activity rather than im‑
paired fibrinolytic potential may be involved in 
modulating angioedema attacks in patients with 
C1INH ‑HAE. However, the major study limitation 
was a small sample size, thus the presented data 
should be interpreted with caution. In order to 
fully understand the pathophysiology of C1INH‑
‑HAE as well as the role of thrombin formation, 
blood clotting, fibrinolysis, and endothelial dam‑
age in this disease, further investigation on larg‑
er group with long ‑term follow ‑up is required.
ARTICLE INFORMATION
ACKNOWLEDGMENTS This study was supported by a grant from 
the National Science Centre (No. UMO ‑2014/13/B/NZ6/00246; to KO).
CONFLICT OF INTEREST None declared.
OPEN ACCESS This is an Open Access article distributed under the terms 
of the Creative Commons Attribution -NonCommercial -ShareAlike 4.0 Inter-
national License (CC BY -NC -SA 4.0), allowing third parties to copy and re-
distribute the material in any medium or format and to remix, transform, and 
build upon the material, provided the original work is properly cited, distrib-
uted under the same license, and used for noncommercial purposes only. For 
commercial use, please contact the journal office at pamw@mp.pl.
HOW TO CITE Obtułowicz K, Dyga W, Natorska J, et al. Elevated thrombin 
generation and factor VIII activity during angioedema attack in patients with 
hereditary C1 inhibitor deficiency. Pol Arch Intern Med. 2019; 129: 936-938. 
doi:10.20452/pamw.15096
